Extrapulmonary Tuberculosis

Tuberculosis (TB), caused by the bacteriumMycobacterium tuberculosis, remains a major global health challenge. In 2019, an estimated 10 million cases and 1.5 million deaths were attributed to TB worldwide ^[1]. It is a complex disease resulting from an intricate interaction between the host and the pathogen, with host genetic factors playing a significant role in susceptibility^[1]. While pulmonary tuberculosis, affecting the lungs, is the most common manifestation,Mycobacterium tuberculosiscan disseminate from the primary site of infection to other parts of the body, leading to extrapulmonary tuberculosis (EPTB).

EPTB occurs when the bacteria spread through the bloodstream or lymphatic system to organs outside the lungs, such as lymph nodes, bones, joints, the pleura, kidneys, or the central nervous system. The specific site of infection and the host’s immune response, which is influenced by genetic predisposition, largely determine the clinical presentation and severity of the disease. For example, tuberculous meningitis, a severe form of EPTB affecting the brain and spinal cord, has been a focus of genetic susceptibility research^[2].

Clinically, EPTB presents a wide spectrum of symptoms, making diagnosis challenging due to its varied and often non-specific manifestations. It may require specialized diagnostic techniques beyond those used for pulmonary TB, including biopsies, advanced imaging, and targeted microbiological cultures. Treatment typically involves multi-drug regimens similar to those for pulmonary TB, though the duration may be extended depending on the affected site and severity.

From a social perspective, EPTB contributes significantly to the global burden of tuberculosis, leading to considerable morbidity, disability, and mortality, especially in immunocompromised individuals and populations in low- to middle-income countries^[1]. The diagnostic complexities and prolonged treatment requirements of EPTB place additional strain on healthcare systems and public health efforts aimed at controlling the disease.

Limitations

Methodological and Statistical Constraints

Genetic association studies for tuberculosis (TB) have often faced significant methodological and statistical challenges, primarily stemming from insufficient sample sizes. Small cohorts limit the statistical power necessary to detect genetic variants with modest effect sizes, which are characteristic of complex diseases, potentially leading to inflated effect estimates for any associations that are identified . Variants in genes involved in immune regulation, cell signaling, and non-coding RNA pathways can influence the body’s ability to contain the infection or prevent its dissemination.

Several single nucleotide polymorphisms (SNPs) are located in genes or regions with known roles in cellular regulation and immune responses. For instance,rs17502738 is found in the ZBTB5 gene, which encodes a zinc finger and BTB domain-containing protein, typically involved in transcriptional regulation. Variants in such transcription factors can alter the expression of downstream genes critical for immune cell development, activation, or inflammatory responses, potentially affecting the host’s defense against M. tuberculosisand contributing to varying disease outcomes^[2]. Similarly, rs149549781 is associated with FOXO3, a forkhead box O transcription factor widely recognized for its pivotal role in regulating cellular processes such as metabolism, oxidative stress resistance, and apoptosis, all of which are essential for effective immune surveillance. Alterations in FOXO3 activity due to this variant could impact the survival and function of immune cells, thereby modulating the host’s capacity to control tuberculous infection and potentially influencing the risk of extrapulmonary disease.

Other variants are located in genes involved in cell surface interactions and signal transduction pathways, which are vital for immune cell communication and response to pathogens. rs10158328 is associated with ADAM15, a member of the A Disintegrin And Metalloproteinase family, which plays a role in cell adhesion, migration, and the proteolytic shedding of cell surface proteins. Variations in ADAM15could affect immune cell trafficking to sites of infection or their ability to interact with infected cells, impacting disease progression^[3]. The variant rs1526554 is found in THSD7A, a gene encoding Thrombospondin Type 1 Domain Containing 7A, which is involved in cell adhesion and angiogenesis, processes crucial for granuloma formation and tissue repair in tuberculosis. Meanwhile,rs6489368 is linked to CACNA1C, which encodes a subunit of a voltage-gated calcium channel; calcium signaling is fundamental for immune cell activation and cytokine production. Lastly,rs34922295 is located near DGKB, a diacylglycerol kinase involved in lipid signaling pathways that are integral to inflammation and immune responses. Variants in these genes could collectively influence the host’s ability to mount an effective immune response, control bacterial replication, and prevent extrapulmonary spread, a complex phenotype influenced by multiple genetic factors ^[4].

Beyond protein-coding genes, certain variants reside in non-coding regions or pseudogenes, which can still exert significant regulatory influence on gene expression. rs10221875 is found within the RNU6-1168P - RNU6-1007P region, which contains pseudogenes related to small nuclear RNAs (snRNAs) critical for mRNA splicing. Such pseudogenes or variants within them can act as regulatory elements, potentially modulating the expression of functional snRNAs or other genes, thereby indirectly affecting cellular processes relevant to immunity. Similarly, rs79675439 is located in the RPS23P5 - NENFP3 region, encompassing pseudogenes for a ribosomal protein and another gene. Pseudogenes, while not coding for functional proteins themselves, can influence the expression of their functional counterparts or participate in RNA-based regulatory networks, potentially impacting protein synthesis and cellular stress responses vital for anti-mycobacterial immunity ^[5]. Finally, rs12580873 is found within the LINC02392 - LINC02822region, which comprises long intergenic non-coding RNAs (lincRNAs). LincRNAs are known to regulate gene expression through diverse mechanisms, including chromatin remodeling and transcriptional control. Variants in these lincRNA regions could alter their structure or expression, subsequently affecting the regulation of nearby or distant genes involved in immune pathways or tissue integrity, thereby influencing susceptibility to extrapulmonary tuberculosis.

Definition and Conceptual Framework

Extrapulmonary tuberculosis (EPTB) refers to active tuberculosis disease that manifests in organs or tissues outside of the lungs. This classification distinguishes it from pulmonary tuberculosis (PTB), which is primarily characterized by respiratory symptoms such as chest pain, fever, and weight loss, along with the detection of acid-fast bacilli in sputum smears and specific findings on chest X-rays^[6]. Tuberculosis, in general, is an infectious disease caused byMycobacterium tuberculosis ^[7]. The infection can lead to an extended natural history, often including a latency period that can span decades before the development of active disease^[3]. EPTB encompasses a wide array of clinical presentations where the bacterium affects various body systems, making it a significant and diverse component of the global tuberculosis burden^[8].

Classification and Clinical Diversity

The classification of extrapulmonary tuberculosis primarily involves categorizing the disease based on the specific anatomical site where the infection manifests. A notable and often severe form of EPTB is tuberculous meningitis, which involves the central nervous system^[2]. The overall phenotypic heterogeneity of tuberculosis-related traits is considerable, suggesting that different clinical presentations and disease outcomes may stem from varied genetic susceptibilities and environmental influences^[3]. This inherent diversity in how EPTB presents across different body systems underscores the complexity of the disease and influences the specific diagnostic and therapeutic strategies employed for each subtype.

Diagnostic Approaches and Criteria

The diagnosis of tuberculosis broadly relies on identifying the presence ofMycobacterium tuberculosisand correlating it with clinical signs and symptoms. For pulmonary tuberculosis, established diagnostic criteria include characteristic clinical symptoms, the microscopic identification of acid-fast bacilli in sputum samples, and specific patterns observed on chest X-rays^[6]. While these specific criteria are tailored for lung involvement, the general detection of M. tuberculosisinfection, which may precede or accompany EPTB, can involve immunological tests like the Tuberculin Skin Test (TST). A positive TST result, typically defined as an induration of 5 millimeters or more, indicates a cellular immune response to mycobacterial antigens^[9]. The definitive diagnosis of EPTB often requires direct evidence of M. tuberculosis from the affected extrapulmonary site through microbiological culture, molecular tests, or histopathological examination of tissue biopsies.

Terminology and Nosological Context

The nomenclature used in discussing tuberculosis provides a structured framework for understanding its various forms and stages. “Tuberculosis” serves as the overarching term for the infectious disease caused byMycobacterium tuberculosis ^[7]. Within this broad category, “pulmonary tuberculosis” specifically refers to the disease affecting the lungs, while “extrapulmonary tuberculosis” is the designation for any manifestation occurring outside the lungs, such as “tuberculous meningitis”^[2]. The progression of M. tuberculosisinfection can involve an initial period of latency, and active disease can subsequently arise either from a new “reinfection” or from the activation of dormant bacteria, referred to as “reactivation cases”^[3]. These terms are essential for accurately classifying the disease, understanding its epidemiology, and guiding clinical management.

Signs and Symptoms

Extrapulmonary tuberculosis (EPTB) encompasses a diverse range of clinical presentations, as theMycobacterium tuberculosisinfection can affect various organs outside the lungs. The clinical picture is highly variable, influenced by the specific site of infection, the patient’s immune status, and genetic predispositions.

Systemic Manifestations and General Symptoms

Extrapulmonary tuberculosis often presents with non-specific systemic symptoms that can overlap with various other conditions, making early diagnosis challenging. Common general symptoms often associated with tuberculosis infection, which can also manifest in extrapulmonary forms, include fever and unexplained weight loss^[6]. These constitutional signs reflect the body’s generalized inflammatory response to Mycobacterium tuberculosisinfection. The presence and severity of these systemic manifestations can vary significantly, often influencing the overall clinical presentation and contributing to diagnostic delays.

Organ-Specific Presentations and Clinical Phenotypes

The clinical presentation of extrapulmonary tuberculosis is highly diverse, depending on the affected organ or site. Tuberculous meningitis (TBM) represents a distinct and severe clinical phenotype of EPTB, where specific clinical parameters are crucial for assessing disease severity and predicting outcomes^[10]. The precise signs and symptoms will vary based on the affected extrapulmonary site, highlighting the heterogeneous nature of the disease. Consequently, the clinical phenotypes of EPTB range broadly, from localized manifestations to more disseminated forms, necessitating a thorough and often site-specific diagnostic approach.

Diagnostic Markers and Assessment Methods

Diagnosis of extrapulmonary tuberculosis often involves a combination of objective and subjective measures, along with laboratory and imaging tools. Routine inflammatory markers, such as erythrocyte sedimentation rate (ESR), are commonly assessed to gauge the systemic inflammatory response^[11]. Furthermore, plasma levels of specific cytokines, including IL-6, sIL-2R, and TNF-α, can serve as valuable biomarkers reflecting the immunological activity associated with tuberculosis^[11]. The Tuberculin Skin Test (TST) is another assessment method used to detect Mycobacterium tuberculosisinfection, particularly noted for its reactivity patterns in specific populations like HIV-positive individuals^[9]. These objective measurements aid in the diagnostic process and provide insights into the disease’s activity and potential severity.

Variability, Prognostic Factors, and Atypical Presentations

The presentation of tuberculosis, including its extrapulmonary forms, exhibits significant inter-individual variation influenced by host factors. Studies indicate potential sex differences in susceptibility to tuberculosis, which may contribute to variations in disease presentation patterns^[12]. For specific EPTB manifestations like tuberculous meningitis, certain genetic factors, such as the LTA4H genotype, have been identified as prognostic indicators for mortality^[10]. Additionally, clinical parameters and routine inflammatory markers are critical in predicting mortality among patients with tuberculous meningitis^[10]. Atypical presentations are also observed, such as altered tuberculin skin test reactivity in HIV-positive individuals, underscoring the influence of co-morbidities on diagnostic indicators ^[9].

Extrapulmonary tuberculosis (EPTB) is a complex disease resulting from a multifactorial interaction between the host and theMycobacterium tuberculosis (Mtb) pathogen. While Mtbinfection is the prerequisite, the development of active disease, particularly in extrapulmonary sites, is influenced by a combination of host genetic factors, environmental exposures, socioeconomic conditions, and the intricate interplay between these elements.

Host Genetic Predisposition

Host genetic factors significantly influence an individual’s susceptibility to tuberculosis, including its extrapulmonary manifestations^[1]. This susceptibility is largely polygenic, involving multiple inherited variants rather than a single gene. Genome-wide association studies (GWAS) have identified several loci associated with Mtbinfection and resistance. For instance, a locus at 10q26.2 has been linked to resistance toMtbinfection, while common variants at 11p13 are associated with general tuberculosis susceptibility^[13]. Conversely, a locus at 5q33.3 has been found to confer resistance to tuberculosis in highly susceptible individuals^[9].

The genetic landscape of tuberculosis susceptibility is complex, with over 100 candidate genes studied, though few associations have shown consistent reproducibility across diverse populations^[2]. Specific forms of EPTB, such as tuberculous meningitis, also show genetic susceptibility, with candidate genes involved in innate immunity identified as potential contributors to risk ^[2]. The phenotypic heterogeneity of tuberculosis-related traits suggests that different stages of infection or disease presentation, including extrapulmonary forms, may result from distinct sets of genetic causal factors^[3].

Environmental and Socioeconomic Determinants

Environmental and socioeconomic factors play a crucial role in the epidemiology and development of tuberculosis, affecting populations disproportionately^[1]. Socioeconomic determinants, such as poverty, inadequate housing, and poor nutrition, are recognized drivers of tuberculosis epidemics and significantly impact disease burden, particularly in low- to middle-income countries where incidence rates can be substantially higher^[2]. These factors contribute to environments that facilitate Mtbtransmission and compromise host immunity, increasing the risk of both initial infection and progression to active disease.

Geographic influences and pathogen variability are also critical environmental considerations. The natural history of Mtbinfection can involve a latency period lasting decades, and the clinical outcomes can be influenced by the specificM. tuberculosisstrain and the inoculum size^[3]. Moreover, geographic variations in pathogen strains and host populations contribute to the complexities of disease manifestation and can influence the likelihood of extrapulmonary dissemination.

Pathogen and Immunological Interactions

The development of extrapulmonary tuberculosis involves intricate interactions between the host’s genetic makeup, immune status, and the characteristics of the infectingMtbstrain. Host genetic predisposition can interact with environmental triggers and the pathogen itself, influencing the course of infection^[1]. For example, a locus at 5q31.1 has been associated with tuberculin skin test reactivity in HIV-positive individuals, highlighting how genetic factors might modulate immune responses in immunocompromised states ^[9].

Comorbidities, particularly conditions that compromise the immune system, significantly increase the risk of developing active tuberculosis and its extrapulmonary forms. HIV infection is a well-established risk factor, as it severely weakens the host’s ability to containMtb, facilitating disease progression and dissemination to extrapulmonary sites^[9]. The interplay between host genetics, the immune modulating effects of comorbidities, and the specific virulence factors of the Mtbstrain collectively determine the likelihood and presentation of extrapulmonary tuberculosis.

Biological Background

Extrapulmonary tuberculosis (EPTB) refers to tuberculosis disease that affects organs outside of the lungs, occurring whenMycobacterium tuberculosis(M.tb) disseminates from the primary site of infection. This form of tuberculosis presents a complex biological challenge, involving intricate host-pathogen interactions, specific genetic susceptibilities, and diverse clinical manifestations across various tissues.

Nature and Pathogenesis of Extrapulmonary Tuberculosis

Extrapulmonary tuberculosis represents a significant manifestation ofMycobacterium tuberculosisinfection, occurring when the bacteria disseminate beyond the lungs. While approximately 5–10% of individuals infected with M.tb develop active tuberculosis disease, EPTB is often observed in about half of these patients, particularly young children, and is frequently associated with “primary” TB within two years of initial infection^[3]. This indicates a complex interplay between the host and pathogen, where the host’s initial immune response may fail to contain the infection locally, leading to systemic spread^[1]. The disease mechanisms involve the ability of M.tb to evade host defenses and establish infection in various tissues, disrupting normal homeostatic processes.

Host Immune Response and Cellular Mechanisms

The host immune system plays a critical role in controlling M. tuberculosisinfection, involving a complex network of molecular and cellular pathways. Innate immunity, orchestrated by various cell types and signaling cascades, is crucial in the initial defense against mycobacteria, with candidate genes involved in this process identified for further investigation^[2]. A key biomolecule in this defense is Interferon-gamma (IFN-γ), and single-gene inborn errors affecting IFN-γ immunity have been linked to childhood tuberculosis, including extrapulmonary forms^[3]. Effective host immunity to mycobacteria relies on well-regulated cellular functions and interactions, which, when compromised, can lead to the development of active disease^[14].

Genetic Factors Influencing Susceptibility

Human genetics significantly contributes to the variability in individual responses to M. tuberculosisand susceptibility to developing active disease^[3]. Genome-wide association studies (GWAS) have identified specific genetic loci associated with tuberculosis susceptibility, such as a locus at 10q26.2 linked to resistance to M.tb infection and common variants at 11p13 associated with general tuberculosis susceptibility^[13]. Furthermore, a chromosome 5q31.1 locus has been associated with tuberculin skin test reactivity, indicating genetic influence on immune responses to the bacterium ^[9]. The LTA4H genotype has also been identified as a predictor of mortality in patients with tuberculous meningitis, a severe form of extrapulmonary TB, highlighting the role of specific gene functions and their regulatory elements in disease outcomes^[2].

Organ-Specific Manifestations and Disease Heterogeneity

Extrapulmonary tuberculosis is characterized by its phenotypic heterogeneity, manifesting in diverse ways depending on the affected organ or tissue. Tuberculous meningitis, for instance, is a severe form of EPTB that specifically impacts the central nervous system, leading to distinct pathophysiological processes and clinical outcomes^[2]. The development of EPTB, often associated with primary TB in young children, suggests that different stages and forms of tuberculosis result from varying sets of genetic causal factors and host-pathogen interactions^[3]. This variability underscores the importance of considering organ-specific effects and tissue interactions, as well as systemic consequences, when studying the biology of EPTB, recognizing that the dynamic nature of the disease is influenced by both host genetics and the specificM. tuberculosis strain.

Pathways and Mechanisms

Extrapulmonary tuberculosis, while distinct from pulmonary forms, shares underlying host-pathogen interactions and immune mechanisms. The development and progression of this disease are heavily influenced by a complex interplay of genetic predispositions, immune signaling, and regulatory networks that dictate the host’s response toMycobacterium tuberculosis.

Genetic Modulators of Host Immunity

The host’s genetic makeup plays a significant role in modulating susceptibility and resistance to Mycobacterium tuberculosisinfection. Common variants at 11p13 have been associated with susceptibility to tuberculosis, indicating specific genetic predispositions that can influence disease development^[14]. Furthermore, a distinct locus at 10q26.2 has been identified across three populations, conferring resistance to M. tuberculosisinfection, which highlights conserved genetic mechanisms of protection^[13]. Similarly, a chromosome 5q31.1 locus is associated with tuberculin skin test reactivity in HIV-positive individuals, underscoring the genetic regulation of specific immune responses to the pathogen ^[9]. These findings collectively emphasize how inherited genetic factors can significantly impact an individual’s ability to control M. tuberculosis and prevent the dissemination leading to extrapulmonary manifestations.

Immune Recognition and Regulatory Networks

The host immune system orchestrates its response to mycobacterial infection through intricate regulatory mechanisms, including the precise control of gene expression and the activity of transcription factors. Candidate genes involved in innate immunity are crucial for host defense and are being investigated for their role in genetic susceptibility to severe forms, such as tuberculous meningitis^[2]. Transcription factors (TF) are central molecular components, acting to regulate gene expression and thus influencing the immune cell’s response and the overall outcome of the infection^[15]. The delicate balance and interaction between specific genetic variants and these regulatory networks determine the effectiveness of the immune response against M. tuberculosis.

Systems-Level Integration of Host Defense

Resistance or susceptibility to M. tuberculosisinfection is not determined by single factors but rather emerges from a complex, systems-level integration of genetic, environmental, and intrinsic influences. These factors collectively shape the human antibody epitope repertoire, which is critical for an effective immune response^[16]. This intricate integration results in genomic-driven phenotypic differences, where an individual’s unique genetic profile significantly impacts their immune responses and clinical course ^[15]. Such network interactions involve the hierarchical regulation of various immune pathways, which can either successfully contain the pathogen or, if dysregulated, allow for its dissemination and the development of extrapulmonary disease^[16].

Pathways in Disease Pathogenesis

Dysregulation within these genetically influenced immune pathways represents a core mechanism contributing to the pathogenesis of tuberculosis, including its extrapulmonary forms. Specific genetic variants can lead to altered immune signaling or impaired effector functions, thereby diminishing the host’s capacity to effectively clear or containM. tuberculosis ^[2]. For example, identified genetic susceptibility factors can predispose individuals to severe manifestations like tuberculous meningitis by compromising essential innate immune responses necessary for pathogen control ^[2]. Elucidating these dysregulated pathways and their underlying genetic determinants is crucial for developing targeted therapeutic strategies and improving outcomes for patients with extrapulmonary tuberculosis.

Clinical Relevance

Extrapulmonary tuberculosis (EPTB) presents unique diagnostic and management challenges due to its diverse manifestations and often paucibacillary nature. Understanding the underlying genetic predispositions and prognostic markers is crucial for improving patient outcomes. Research into host genetics, disease progression, and treatment response provides valuable insights for personalized medicine approaches and targeted public health interventions.

Genetic Insights into Susceptibility and Risk Stratification

Host genetic factors significantly influence an individual’s susceptibility to Mycobacterium tuberculosisinfection and the progression to active disease, given that only a small percentage of infected individuals develop overt illness^[1]. Genome-wide association studies (GWAS) have identified specific genetic loci, such as those at 10q26.2 and 11p13, associated with resistance or susceptibility to tuberculosis across diverse populations^[13]. These genetic insights are crucial for risk stratification, enabling the identification of high-risk individuals who may benefit from personalized prevention strategies and intensified monitoring, particularly considering the varied manifestations of the disease, including extrapulmonary forms^[4]. Understanding these genetic predispositions, which can also include sex-specific associations, guides targeted interventions and moves towards a more personalized medicine approach for disease control^[12].

Prognostic Markers for Disease Outcomes

The identification of prognostic markers is vital for predicting disease outcomes and guiding clinical management in extrapulmonary tuberculosis, particularly in severe forms like tuberculous meningitis (TBM)^[10]. Studies have demonstrated that a combination of clinical parameters, routine inflammatory markers, and specific genotypes, such as the LTA4Hgenotype, can effectively predict mortality among patients with TBM, which represents a critical complication of the disease^[10]. Beyond specific forms, broader genetic and molecular markers, including blood RNA signatures, are being explored for their ability to predict general tuberculosis disease risk and progression^[17]. These prognostic tools facilitate early identification of patients at higher risk of adverse outcomes, allowing for timely adjustments to treatment and intensified monitoring strategies to improve long-term patient care.

Clinical Applications: Diagnostic Utility and Monitoring

The integration of genetic and conventional risk factors offers enhanced diagnostic utility and informs monitoring strategies for tuberculosis, including its extrapulmonary manifestations^[4]. For instance, in tuberculous meningitis, understanding genetic susceptibility and the role of candidate genes involved in innate immunity can refine diagnostic approaches and guide therapeutic decisions ^[10]. Furthermore, the development of polygenic risk prediction models and the identification of blood RNA signatures represent promising avenues for assessing an individual’s overall risk of developing active tuberculosis^[18]. These advancements are critical for implementing stratified prevention and early treatment initiation, thereby improving patient outcomes across the spectrum of disease presentations and allowing for more targeted interventions and efficient allocation of resources.

Key Variants

RS ID	Gene	Related Traits
rs17502738	ZBTB5	daytime rest measurement extrapulmonary tuberculosis
rs10158328	ADAM15	extrapulmonary tuberculosis
rs149549781	FOXO3	extrapulmonary tuberculosis
rs10221875	RNU6-1168P - RNU6-1007P	extrapulmonary tuberculosis
rs79675439	RPS23P5 - NENFP3	extrapulmonary tuberculosis
rs1526554	THSD7A	tuberculosis extrapulmonary tuberculosis
rs6489368	CACNA1C	extrapulmonary tuberculosis
rs12580873	LINC02392 - LINC02822	extrapulmonary tuberculosis
rs34922295	DGKB	extrapulmonary tuberculosis

Frequently Asked Questions About Extrapulmonary Tuberculosis

These questions address the most important and specific aspects of extrapulmonary tuberculosis based on current genetic research.

---

1. My uncle had EPTB; am I more likely to get it?

Yes, there’s a good chance genetic factors passed down in your family could play a role in your susceptibility to EPTB. Host genetics significantly influence how your body responds to the bacteria, which can affect whether you develop the disease and how severe it becomes. While not solely genetic, a family history suggests you might share some of those predisposing factors.

2. Why did I get EPTB when my friend didn’t, even after exposure?

Your genetic makeup likely plays a significant role in this difference. Even with similar exposure, individual genetic factors influence your immune response to Mycobacterium tuberculosis. These predispositions can determine whether you develop EPTB and how your body fights off the infection, leading to varied outcomes between people.

3. Does my ethnic background change my EPTB risk?

Yes, your ethnic background can influence your EPTB risk. Genetic susceptibility to tuberculosis isn’t uniform globally; differences in ancestral backgrounds and gene frequencies mean that genetic risk factors can vary significantly between different populations. Research needs to consider this diversity to fully understand specific risks.

4. Why do some EPTB cases get so severe, like meningitis?

The severity and specific presentation of EPTB, such as tuberculous meningitis, are strongly influenced by your host immune response, which in turn is shaped by your genetic predisposition. Certain genetic factors can make individuals more prone to severe forms when the bacteria disseminate to critical areas like the brain and spinal cord.

5. Is EPTB different for kids, or for women compared to men?

Yes, evidence suggests that the genetic predispositions for TB can differ between children and adults, and also vary by sex. This means that the specific genetic factors influencing susceptibility and disease progression might not be the same for everyone, depending on their age and sex.

6. Can living in a crowded place make my genetic risk for EPTB worse?

Yes, environmental factors like living conditions can certainly interact with your genetic predisposition. While your genetics might increase your susceptibility, social determinants and environmental exposures are powerful confounders that can independently drive disease risk and worsen outcomes, making the disease more likely to develop.

7. If I have a strong family history, can I still prevent EPTB?

While genetics play a significant role, the development of active EPTB is a complex interplay of many factors. Environmental and social determinants, such as socioeconomic status or co-existing infections, also profoundly influence disease risk. Managing these non-genetic factors can still be crucial in reducing your overall risk, even with a genetic predisposition.

8. Why do some people never get EPTB, even if exposed a lot?

Some individuals possess genetic variations that confer resistance to Mycobacterium tuberculosisinfection, even in highly susceptible populations or with significant exposure. Your unique genetic makeup determines how effectively your immune system can prevent the bacteria from causing active disease, leading to natural resistance in some.

9. Could a genetic test tell me my personal EPTB risk?

Currently, it’s challenging for a single genetic test to give you a definitive personal EPTB risk. While twin studies show a significant genetic component, the genetic architecture is complex, and many identified genetic variants have modest effects. Research is ongoing, but comprehensive, reliable genetic risk prediction for EPTB is still developing.

10. Why is it hard to find clear answers about EPTB genetics?

Research into EPTB genetics faces several challenges. Studies often have small sample sizes, limiting their power to find subtle genetic links, and findings can be hard to replicate across different populations. Also, the broad ways “tuberculosis” is defined in studies can dilute specific genetic signals related to EPTB.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] Swart Y et al. “Local Ancestry Adjusted Allelic Association Analysis Robustly Captures Tuberculosis Susceptibility Loci.”Front Genet, vol. 12, 2021, p. 716558.

[2] Schurz H et al. “Multi-ancestry meta-analysis of host genetic susceptibility to tuberculosis identifies shared genetic architecture.”Elife, vol. 13, 2024.

[3] Grant, A. V. et al. “A genome-wide association study of pulmonary tuberculosis in Morocco.”Hum Genet, vol. 135, no. 3, 2016, pp. 317-327. PMID: 26767831.

[4] Hong EP, et al. “Risk prediction of pulmonary tuberculosis using genetic and conventional risk factors in adult Korean population.”PLoS One, 2017.

[5] Luo, Y., et al. “Early progression to active tuberculosis is a highly heritable trait driven by 3q23 in Peruvians.”Nat Commun, vol. 10, no. 1, 2019, p. 3762.

[6] Curtis, J et al. “Susceptibility to tuberculosis is associated with variants in the ASAP1 gene encoding a regulator of dendritic cell migration.”Nat Genet, vol. 47, no. 5, 2015, pp. 523-28. PMID: 25774636.

[7] Zumla, A et al. “Tuberculosis.”N Engl J Med, vol. 368, no. 8, 2013, pp. 745-755. PMID: 23425167.

[8] Dye, C et al. “Trends in tuberculosis incidence and their determinants in 134 countries.”Bull World Health Organ, vol. 87, no. 9, 2009, pp. 683-691. PMID: 19783781.

[9] Sobota, R. S. et al. “A chromosome 5q31.1 locus associates with tuberculin skin test reactivity in HIV-positive individuals from tuberculosis hyper-endemic regions in east Africa.”PLoS Genet, 2017.

[10] Schurz H, et al. “Deciphering Genetic Susceptibility to Tuberculous Meningitis.” Front Neurol, 2022.

[11] Zheng, R., et al. “Genome-wide association study identifies two risk loci for tuberculosis in Han Chinese.”Nat Commun, vol. 9, no. 1, 2018, p. 4075.

[12] Schurz H et al. “A Sex-Stratified Genome-Wide Association Study of Tuberculosis Using a Multi-Ethnic Genotyping Array.”Front Genet, vol. 9, 2019, p. 678.

[13] Quistrebert J, et al. “Genome-wide association study of resistance to Mycobacterium tuberculosis infection identifies a locus at 10q26.2 in three distinct populations.”PLoS Genet, 2021.

[14] Thye T, et al. “Common variants at 11p13 are associated with susceptibility to tuberculosis.”Nat Genet, 2012.

[15] Rivera, N. V. et al. “High-Density Genetic Mapping Identifies New Susceptibility Variants in Sarcoidosis Phenotypes and Shows Genomic-driven Phenotypic Differences.” Am J Respir Crit Care Med, 2016.

[16] Andreu-Sanchez, S. et al. “Phage display sequencing reveals that genetic, environmental, and intrinsic factors influence variation of human antibody epitope repertoire.” Immunity, 2023.

[17] Zak DE, et al. “A blood RNA signature for tuberculosis disease risk: a prospective cohort study.”Lancet, 2016.

[18] Chatterjee N, Shi J, Garcı´a-Closas M. “Developing and evaluating polygenic risk prediction models for stratified disease prevention.”Nat Rev Genet, 2016.